Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in patients with Anaplastic Large Cell Lymphoma.

Statements

Source and description
Adcetris (brentuximab vedotin) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.